Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Daniel A. Camardo net worth and biography

Daniel Camardo Biography and Net Worth

EVP of Horizon Therapeutics Public

Daniel A. Camardo joined Horizon in September 2015 and has held various commercial leadership roles, most recently serving as group vice president and general manager of our inflammation business. Camardo has more than 20 years of pharmaceutical industry experience working primarily in sales leadership, corporate analytics, commercial strategy and operations. Camardo is currently responsible for the rare disease business (ACTIMMUNE, PROCYSBI, RAVICTI), the inflammation business, access and reimbursement and commercial operations.

Before joining Horizon, Camardo was vice president sales and operations at Clarus Therapeutics, a start-up company focused on men's health. Camardo spent 11 years at Astellas Pharma helping develop its commercial business from a U.S. market entry in 2003 to a portfolio of 11 marketed medicines and more than $3.5 billion in net sales. Camardo has extensive launch experience having been involved in more than 10 medicine launches across specialty and rare diseases.

Camardo holds a Master of Business Administration from Kellogg School of Management and a bachelor's degree in economics and mathematics from the University of Rochester.

What is Daniel A. Camardo's net worth?: The estimated net worth of Daniel A. Camardo is at least $5.12 million as of March 30th, 2021. Mr. Camardo owns 43,997 shares of Horizon Therapeutics Public stock worth more than $5,116,851 as of April 18th. This net worth estimate does not reflect any other investments that Mr. Camardo may own. Learn More about Daniel A. Camardo's net worth.
How do I contact Daniel A. Camardo?: The corporate mailing address for Mr. Camardo and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Daniel A. Camardo's contact information.
Has Daniel A. Camardo been buying or selling shares of Horizon Therapeutics Public?: Daniel A. Camardo has not been actively trading shares of Horizon Therapeutics Public within the last three months. Most recently, Daniel A. Camardo sold 12,900 shares of the business's stock in a transaction on Tuesday, March 30th. The shares were sold at an average price of $85.50, for a transaction totalling $1,102,950.00. Following the completion of the sale, the executive vice president now directly owns 43,997 shares of the company's stock, valued at $3,761,743.50. Learn More on Daniel A. Camardo's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Daniel A. Camardo Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/30/2021	Sell	12,900	$85.50	$1,102,950.00	43,997
11/6/2020	Sell	3,500	$76.76	$268,660.00	30,829

Daniel A. Camardo Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03